Romosozumab (Evenity) for Postmenopausal Osteoporosis
Date: June 3, 2019
Issue #:
1573Summary:
The FDA has approved romosozumab-aqqg (Evenity–
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
R omosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) re...
Source: The Medical Letter - May 1, 2019 Category: Drugs & Pharmacology Authors: admin Tags: abaloparatide Aclasta Actonel Alendronate Atelvia Binosto Bisphosphonates Boniva Denosumab Evenity Evista Forteo Fosamax Fosavance Ibandronate Osteoporosis Postmenopausal osteoporosis Prolia Raloxifene Reclast rised Source Type: research
Coding Corner Answers: A Drug Administration Quiz
Take the challenge. C—This claim cannot be coded without querying the infusion nurse and physician. There must be documentation of the patient’s weight to document the correct dosage of the medication to be given to the patient. Also the start time and the completion time of the infusion must be documented to know which drug... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - November 19, 2018 Category: Rheumatology Authors: From the College Tags: Billing/Coding From the College adalimumab Billing & Coding denosumab ibandronate sodium infliximab Source Type: research
Coding Corner Questions: A Drug Administration Quiz
A 70–year-old female patient with rheumatoid arthritis affecting multiple joints who is rheumatoid-factor positive but without organ or system failure returns for her third infliximab infusion. She is scheduled to receive 500 mg of the drug. How should this encounter be coded? 96413, 96415, J1745 x 50; ICD 10: M05.79 96413, 96415, J1745 x 50;... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - November 19, 2018 Category: Rheumatology Authors: From the College Tags: Billing/Coding From the College adalimumab Billing & Coding denosumab ibandronate sodium infliximab Source Type: research
Comparison Table: Drugs for Postmenopausal Osteoporosis (online only)
Date: June 19, 2017
Issue #:
1523Summary:
View the Comparison Table: Drugs for Postmenopausal Osteoporosis (Source: The Medical Letter)
Source: The Medical Letter - June 12, 2017 Category: Drugs & Pharmacology Authors: admin Tags: abaloparatide Actonel Alendronate Atelvia bazedoxifene Binosto Boniva Denosumab Duavee Estrogens Evista Forteo Fosamax Ibandronate Miacalcin Osteoporosis Postmenopausal osteoporosis Prolia Raloxifene Reclast risedro Source Type: research
Inhibitory actions by ibandronate sodium, a nitrogen-containing bisphosphonate, on calcium-activated potassium channels in Madin-Darby canine kidney cells
Publication date: Available online 28 August 2015 Source:Toxicology Reports Author(s): Sheng-Nan Wu, Hui-Zhen Chen, Yu-Hung Chou, Yan-Ming Huang, Yi-Ching Lo The nitrogen-containing bisphosphonates used for management of the patients with osteoporosis were reported to influence the function of renal tubular cells. However, how nitrogen-containing bisphosphates exert any effects on ion currents remains controversial. The effects of ibandronate (Iban), a nitrogen-containing bisphosphonate, on ionic channels including two types of Ca2+-activated K+ (KCa) channels, namely, large-conductance KCa (BKCa) and interme...
Source: Toxicology Reports - August 29, 2015 Category: Toxicology Source Type: research
Impurity profiling of ibandronate sodium by HPLC–CAD
Publication date: 10 October 2015 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 114 Author(s): Oliver Wahl , Ulrike Holzgrabe The modern bisphosphonate drug ibandronate sodium, a challenging candidate for impurity profiling, was analyzed using high performance liquid chromatography (HPLC) combined with corona charged aerosol detection (CAD). Separation was achieved on a mixed mode column combining hydrophobic C18 and strong anion exchange retention mechanisms using a mass spectrometer compatible volatile mobile phase consisting of trifluoroacetic acid and acetonitrile while gradient elution was app...
Source: Journal of Pharmaceutical and Biomedical Analysis - June 17, 2015 Category: Drugs & Pharmacology Source Type: research
Denial of Preliminary Injunction Upheld by Federal Circuit; Generic Companies Seek to Introduce Their Versions of Boniva
Biotechnology Law Report Feb 2013, Vol. 32, No. 1: 47-48. (Source: Biotechnology Law Report)
Source: Biotechnology Law Report - April 4, 2013 Category: Medical Law Tags: article Source Type: research
